Posted inPharmaceutical
Systech Launches ST15S and ST16P Pharma Packaging Stations
Systech launches ST15S and ST16P stations that combine serialization, aggregation and labelling for drug makers and CDMOs. What they do, what is unknown.
Posted inPharmaceutical
Neurosterix Completes Phase 1 of NTX-253, an M4 Drug for Schizophrenia
Neurosterix completed Phase 1 of NTX-253, an oral M4 modulator for schizophrenia, and plans Phase 2. What was tested and what is not yet public.
Posted inPharmaceutical
Lakewood-Amedex Reports Positive Preclinical Data for Bisphosphocin Antimicrobials
Lakewood-Amedex reports preclinical Bisphosphocin data in urinary and lung infection models, including up to 97% E. coli reduction in rodents.
Posted inPharmaceutical
Axplora Advances Axotecan to Establish European Exatecan Supply for ADC Developers
Axplora completes first R&D batches of exatecan, an ADC payload starting material, aiming for European GMP supply by late 2027.
Posted inPharmaceutical
Ofichem to Acquire Kinentia Biosciences to Expand Drug Substance CDMO Business in US
Ofichem agrees to acquire New York CDMO Kinentia Biosciences, adding a US drug substance site to its Dutch and Swedish network. Terms undisclosed.
Posted inPharmaceutical
Cerevance Reports Positive Phase 3 Results for Solengepras in Parkinson’s Disease
Cerevance says Phase 3 ARISE met its primary endpoint: solengepras cut daily OFF time by 0.61 hours versus placebo in Parkinson’s patients.
Posted inPharmaceutical
Beactica Therapeutics Selects BEA-28 as Preclinical Candidate for Solid Tumours
Beactica selects BEA-28, a first-in-class TEAD degrader, for solid tumours, with data on KRAS inhibitor resistance. See the risks and next steps.
Posted inPharmaceutical
Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeted Therapies
Italfarmaco and VeriSIM Life partner on AI-driven HDAC-targeted therapies for neuromuscular, fibrotic and rare diseases in a deal worth over $100M.
Posted inPharmaceutical
Lundbeck Reports Phase Ib Results for Lu AF28996 in Advanced Parkinson’s Disease
Lundbeck reports Phase Ib data for Lu AF28996 in advanced Parkinson’s: ON-time up 3.6 hours a day. What the open-label results mean and what Phase II will test.
Posted inPharmaceutical
Piramal Pharma Solutions Opens New Microbiology Laboratory at Kentucky Sterile Injectables Facility
Piramal Pharma Solutions opens a new microbiology laboratory in Lexington, Kentucky, tripling test space and targeting up to 50% faster testing.